For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Leuprolide
Illustration for Leuprolide

THE PEPSRADAR ENCYCLOPEDIA

Leuprolide

GnRH-related control of reproductive hormones

Prescription medicines · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Leuprolide · KEY FACTS

Content updated · how dates work

Saved peptides

Half-life source: FDA label (Vabrinty) on DailyMed ↗

What is Leuprolide?

Leuprolide is a GnRH agonist used to control sex-hormone signaling in several conditions. It belongs to a different pathway from growth-hormone secretagogues.

Biological role or research focus

GnRH-related control of reproductive hormones.

The clinical effect depends on sustained treatment and the condition; it should not be grouped with growth-hormone releasers.

Role reference: MedlinePlus · Leuprolide ↗

Names you may encounter

Lupron

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
GnRH agonist
Main research area
Reproductive-hormone suppression
Evidence featured
Human randomized trial
Source check
October 4, 2026

Source: MedlinePlus · Leuprolide ↗

Quick answers

Is Leuprolide FDA approved?
Yes. Lupron Depot (e.g., NDA 019732), Eligard, Fensolvi and Camcevi for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty (indication varies by product). Source ↗
Is Leuprolide safe?
Approved GnRH agonist used for prostate cancer and other hormone conditions; it causes an early hormone surge and hot flashes and may raise heart, diabetes and bone-loss risks. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
Is Leuprolide banned in sport?
Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.1 Testosterone-stimulating peptides in males). Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

1 Human research
StudyTypePopulation / model
Historical prostate-cancer comparison (1984)Human randomized trial199 patients with previously untreated metastatic prostate cancer.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human randomized trial · 1984

Historical prostate-cancer comparison

Leuprolide versus diethylstilbestrol for metastatic prostate cancer.

Population / model
199 patients with previously untreated metastatic prostate cancer.
Study design
Leuprolide versus diethylstilbestrol, with crossover permitted on progression or intolerable effects.
Main finding
Hormonal suppression and overall response were similar; adverse-effect patterns differed. One-year survival was not significantly different.
Limits & context
This is historical evidence against an older comparator, not a ranking of today’s treatment options. Prostate-cancer findings do not establish benefit for every other leuprolide indication.

Source: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

40 registered studies name Leuprolide as an intervention among the 100 most recently updated of 520 search results; 30 are recruiting or under way, 1 has not started recruiting yet, 8 completed and 1 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081 · Novartis Pharmaceuticals
Active, not recruitingPhase 32024-02-281466
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
NCT04423211 · ECOG-ACRIN Cancer Research Group
RecruitingPhase 32020-10-08804
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT04787744 · VA Office of Research and Development
Active, not recruitingPhase 2 / Phase 32021-07-01378
Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors
NCT06169124 · National Cancer Institute (NCI)
CompletedPhase 22024-02-0817
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
NCT00544830 · City of Hope Medical Center
Active, not recruitingPhase 22006-08-0729
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837 · Pfizer
Active, not recruitingPhase 32014-12-171068
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
NCT05593497 · VA Office of Research and Development
RecruitingPhase 22024-05-3130
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
NCT01674140 · SWOG Cancer Research Network
Active, not recruitingPhase 32013-09-121939

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 40 listed studies.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. ↗
The New England journal of medicine · 2023 Oct 19 · Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. ↗
The New England journal of medicine · 2020 Jun 4 · Clinical Trial, Phase III, Comparative Study, Equivalence Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Leuprolide. ↗
· 2026 Jan · Study Guide

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. ↗
The New England journal of medicine · 2026 Feb 5 · Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, Multicenter Study, Comparative Study

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Approved GnRH agonist used for prostate cancer and other hormone conditions; it causes an early hormone surge and hot flashes and may raise heart, diabetes and bone-loss risks.

Human safety data: FDA label

This entry follows the Vabrinty label for advanced prostate cancer; other leuprolide products are approved for other uses and groups and have their own labels. Evidence comes from clinical trials and postmarketing reports for GnRH agonists.

Take extra care with: Heart or blood pressure problemsDiabetes or blood-sugar medicinesCancer, now or in the pastPregnancy or breastfeeding

From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

  • People allergic to GnRH, GnRH agonist drugs or any product component

Interactions

  • Drugs that prolong the QT interval: added heart rhythm risk with androgen deprivation
  • Drugs linked to seizures, such as bupropion and SSRIs: seizures have been reported during leuprolide treatment

Serious risks

  • Tumor flare early in treatment: bone pain, urinary blockage or spinal cord compression
  • High blood sugar and new diabetes
  • Heart attack, sudden cardiac death and stroke reported in men
  • QT prolongation and seizures
  • Severe skin reactions such as Stevens-Johnson syndrome
  • Fetal harm in pregnancy; rare pituitary apoplexy

Common side effects

  • hot flashes and sweating
  • fatigue
  • malaise
  • testicular shrinkage
  • decreased bone density

Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Vabrinty (leuprolide) prescribing information ↗

Key precautions

Bone-density loss, hot flashes, mood changes, and metabolic or cardiovascular concerns can matter. Pregnancy is incompatible with these treatment uses; specific contraindications and monitoring belong to the product label.

Source: MedlinePlus · Leuprolide ↗

Regulatory status

U.S. FDA approval
Approved
Lupron Depot (e.g., NDA 019732), Eligard, Fensolvi and Camcevi for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty (indication varies by product). source
FDA compounding (503A bulk list)
Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source
World Anti-Doping Agency (2026)
Prohibited, named on the list · S2.2.1 Testosterone-stimulating peptides in males
Named explicitly as a GnRH agonist analogue ("leuprorelin"); prohibited in males. source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Clinical uses & product context

Product-dependent uses include prostate cancer, central precocious puberty, endometriosis, and fibroid-associated anemia. Evidence for one indication should not be substituted for another.

Source: MedlinePlus · Leuprolide ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Why there are no prices here

This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.

Mechanism & research rationale

Sustained GnRH-pathway stimulation ultimately suppresses gonadal hormone production. The resulting clinical effect depends on the treatment duration and the condition.

Source: MedlinePlus · Leuprolide ↗

Molecular structure

Leuprolide: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 657181 ↗

Questions worth asking

  • Which indication and formulation does the source describe?
  • Does the video make a broader claim than the source supports?
  • The clinical effect depends on sustained treatment and the condition; it should not be grouped with growth-hormone releasers.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Is leuprolide intended to boost testosterone?

Sustained therapeutic use generally aims at suppression of reproductive hormones. It should not be grouped with testosterone-enhancement products.

Source: MedlinePlus · Leuprolide ↗

Why include an older cancer study?

It documents the clinical evidence history, while its older comparator limits relevance to today’s treatment choices.

Source: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Leuprolide

Download illustration ↓Source record ↗
Leuprolide 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.